THE ONLY PDE4 INHIBITOR APPROVED TO TREAT PLAQUE PSORIASIS
While the exact way in which Otezla helps improvesymptoms of plaque psoriasis isn’t completelyunderstood, here’s what we do know:
- Otezla works inside inflammatory cells to reducePDE4 activity
- A reduction in PDE4 activity is thought to helpreduce the overactive inflammation that happensin people with psoriasis
- This reduction in overactive inflammation leads to areduction in symptoms of plaque psoriasis
- Otezla helps decrease redness, thickness, and scaliness of plaques
Otezla Via Wiki: Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. It may also be useful for other immune system related inflammatory diseases. The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4) and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells. It is taken by mouth.
Possibilities for Hidradenitis suppurativa (HS) patients via JAAD: Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients – Journal of the American Academy of Dermatology
Despite the many therapeutic approaches available for hidradenitis suppurativa, there is still a need for effective medications to treat moderate and severe forms of the disease. In this study, we assessed the efficacy of the oral phosphodiesterase 4 inhibitor apremilast (30 mg, twice a day) in the management of 9 patients with moderate to severe hidradenitis suppurativa (Hurley stage II-III) who had responded poorly to other treatments.
Although it has many antiinflammatory effects, the mechanism by which apremilast may work in hidradenitis suppurativa is unknown. However, therapy with a phosphodiesterase 4 inhibitor, such as apremilast, which can modulate key pro- and antiinflammatory mediators, such as tumor necrosis factor–α, interleukin-23 (IL) and IL-12 and chemoattraction via regulation of IL-8 and interferon-γ–induced protein 10 expression, might suppress the cellular mechanisms involved and expression of many upregulated cytokines in hidradenitis suppurativa.
READ THE FULL SOURCE: jaad.org
© 2017 by the American Academy of Dermatology, Inc.